JNJ

169.59

+0.33%↑

NVS

117.16

-0.7%↓

ABT

125.67

-0.1%↓

MDT

92.35

+0.27%↑

ELV.US

280.42

-5.39%↓

JNJ

169.59

+0.33%↑

NVS

117.16

-0.7%↓

ABT

125.67

-0.1%↓

MDT

92.35

+0.27%↑

ELV.US

280.42

-5.39%↓

JNJ

169.59

+0.33%↑

NVS

117.16

-0.7%↓

ABT

125.67

-0.1%↓

MDT

92.35

+0.27%↑

ELV.US

280.42

-5.39%↓

JNJ

169.59

+0.33%↑

NVS

117.16

-0.7%↓

ABT

125.67

-0.1%↓

MDT

92.35

+0.27%↑

ELV.US

280.42

-5.39%↓

JNJ

169.59

+0.33%↑

NVS

117.16

-0.7%↓

ABT

125.67

-0.1%↓

MDT

92.35

+0.27%↑

ELV.US

280.42

-5.39%↓

Search

Cassava Sciences Inc

Cerrado

SectorSalud

2.52 -6.67

Resumen

Variación precio

24h

Actual

Mínimo

2.47

Máximo

2.7

Métricas clave

By Trading Economics

Ingresos

4.2M

-23M

Empleados

30

EBITDA

5.7M

-24M

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

34M

111M

Apertura anterior

9.19

Cierre anterior

2.52

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Cassava Sciences Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

27 sept 2024, 10:48 UTC

Principales Movimientos del Mercado

Cassava Sciences Shares Lower Premarket on $40 Million Penalty to Settle Doctored Data Claims

27 sept 2024, 18:36 UTC

Ganancias

These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More -- Barrons.com

27 sept 2024, 09:15 UTC

Acciones populares

Stocks to Watch Friday: Bristol Myers Squibb, EchoStar, Costco -- WSJ

Comparación entre iguales

Cambio de precio

Cassava Sciences Inc Esperado

Consenso

By TipRanks

0 ratings

0

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.56 / 1.7Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.